BDSX Insider: John Patience Receives 1,144 RSUs; Vesting Through Dec 31, 2025

Rhea-AI Filing Summary

John Patience, a director of Biodesix, Inc. (BDSX), reported receipt of 1,144 restricted stock units (RSUs) effective 09/30/2025. The filing notes a one-for-twenty reverse stock split effective 09/15/2025 and states the reported share figures have been adjusted for that split. The RSUs represent contingent rights to receive one share each and vest in three substantially equal installments on 06/30/2025, 09/30/2025, and 12/31/2025, generally subject to continued service, and have no expiration date. The report discloses indirect holdings through Patience Enterprises LP (107,664 shares), the John Patience Living Trust dated 7/23/1993 (241,480 shares), and holdings attributed to a spouse (2,649 shares). The Form is signed by Robin H. Cowie as attorney-in-fact for John Patience on 10/02/2025.

Positive

• 1,144 RSUs granted/reported on 09/30/2025, aligning executive compensation with equity
• RSUs have no expiration date and vest in three equal installments, providing clear vesting schedule

Negative

• None.

Insights

Insider Transactions Analyst

Reporting shows a small issuance of 1,144 RSUs and adjusted holdings after a 1-for-20 reverse split.

The filing documents that 1,144 restricted stock units were reported on 09/30/2025, each convertible to one share and vesting across three dates in 2025, with no expiration.

The Reporting Person also discloses substantial indirect holdings via Patience Enterprises LP and the John Patience Living Trust, with the specified share totals adjusted for the reverse split.

Monitorable item: the next RSU vest date is 12/31/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PATIENCE JOHN

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chairman

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		M		1,144(1)	A	(2)	21,518(1)	D
Common Stock								107,664(1)	I	By Patience Enterprises LP(3)
Common Stock								241,480(1)	I	By John Patience Living Trust dated 7/23/1993(4)
Common Stock								2,649(1)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	09/30/2025		M			1,144(1)	(5)	(5)	Common Stock	1,144(1)	$0	1,143(1)	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

2. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

4. The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).

5. These RSUs vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for John Patience	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did John Patience report in the Form 4 for BDSX?

The Form 4 reports receipt of 1,144 restricted stock units (RSUs) on 09/30/2025 and discloses indirect holdings through entities and a trust.

How were the reported share figures adjusted?

All reported share figures were adjusted to reflect a one-for-twenty reverse stock split effective 09/15/2025.

When do the reported RSUs vest?

The RSUs vest in three substantially equal installments on 06/30/2025, 09/30/2025, and 12/31/2025, subject to continued service, and have no expiration date.

What indirect holdings does the filing disclose?

The filing discloses indirect holdings of 107,664 shares via Patience Enterprises LP, 241,480 shares via the John Patience Living Trust, and 2,649 shares attributed to a spouse.

Who signed the Form 4 and when?

The Form 4 is signed by Robin H. Cowie as Attorney-in-Fact for John Patience on 10/02/2025.